Thrombotic thombocytopenic purpura (TTP) is characterized by a reduction in the von Willebrand cleavage protein ADAMTS-13, caused mainly by autoimmunity. Plasmapheresis is the standard of care achieving complete remission (CR) in 77-83% of cases but figures are variable depending on clinical context and ADAMTS-13 activity. Relapse is frequent in patients with <10% ADAMTS-13, and has been reported in 34-41% of cases. In most of these patients, an inhibitor against ADAMS-13 is detected thus, an effective frontline immunosuppressive treatment is needed to prevent relapses. Originally rituximab was used as a 2nd line therapy in patients with relapsed and refractory TTP aiding to achieve CR and to reduce relapse rates. The assumption that B cell population may be smaller in patients with autoimmune diseases than in neoplasia supported low-dose rituximab use and therefore, we administered plasmapheresis and low-dose rituximab as frontline therapy in 11 patients with a first TTP episode. Newly diagnosed TTP Patients >15 years received plasmapheresis with 1-2 exchanges daily until CR and rituximab 100 mg/dose/week for 4 consecutive weeks, starting the 1st dose immediately after the 2nd or 3rd plasma exchange. Relapse was defined as readmission with thrombocytopenia (< 100 × 109/L), schistocytes in peripheral blood, and ADAMTS-13 <10% after discharge. Between March 2011-March 2015, eleven patients were included; three men (27%) and eight women (73%), median age was 34 years (15-46). The median follow-up is 22 months (range 4-49) and for patients evaluable for ADAMTS-13 activity (n=8) 18 months (range 4-34). Two patients had seizures and mucocutaneous bleeding, 7 numbness, confusion and petechiae and 2 severe headache. Only 2 patients had renal damage at diagnosis (creatinine>1.2). Five patients had additional comorbidities (two diabetes mellitus, two HIV positive and one hypothyroidism) Median laboratory parameters at diagnosis: platelets 11 X 10⁹/L (range 7-27.4 X 10⁹/L), LDH 1822 U/L (range 705-8220 U/L, normal 70-180 U/L), hemoglobin 6 g/dL (range 4.2-11.8 g/dL). ADAMTS-13 activity was determined in 8 patients at diagnosis and in all of them was <10% (normal 40-130%). ADAMTS-13 autoantibody titer was determined in 7 patients and in all of them was >18 units/ml (ref: negative <12, undetermined 12-15, positive > 15 units/ml), shigella toxin was negative in all patients. The median number of plasmapheresis exchanges until CR was 7 (range 4-12)andprednisone at 1 mg/kg was administered to 6 patients. The estimated two-year relapse-free survival was 90%. One HIV+ patient suffered a relapse at 8 months follow-up. A high antibody titer against ADAMTS-13 was detected at relapse with no ADAMTS-13 activity and the patient was retreated with plasmapheresis (3 exchanges) and low-dose rituximab as described and has been in CR for 4 months. There were no complications related to plasmapheresis or rituximab infusion. According to our results low-dose rituximab and plasma exchange are effective in achieving rapid and sustained response in TTP. Of note, the median of plasmapheresis needed to CR (7, range 4-12) was lower than that reported for patients with <10% ADAMTS-13 activity (19 procedures) (Kremer Hovinga JA et al Blood 2010). In our series, median follow-up for patients evaluable for severe ADAMTS-13 deficiency was 18 months, and only one HIV-positive patient relapsed at the 8th month. Our study suggest that frontline low-dose rituximab and plasmapheresis are effective as frontline treatment for TTP. This combination is associated with relatively rapid response and low relapse rate in previously untreated patients, however, a prospective clinical trial is needed to effectively demonstrate if rituximab 100 mg x 4 weekly dose is as effective as the conventional 375 mg/m2 X 4 weekly dose. Disclosures Off Label Use: Rituximab an anti CD monoclonal antibody is used in our work to deplete B cell population therefore stop the production of autoatibodies against ADAMTS-13.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.